Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new bispecific antibody gets a regulatory boost. The FDA has granted fast track designation to cesalatamig (AI-081) for non-small cell lung cancer (NSCLC) that has progressed after both immunotherapy and platinum-based chemotherapy. The drug simultaneously targets PD-1 and VEGF, backed by early signals from the ongoing global BiPAVE-001 phase 1/2 trial program.
A new contender enters the post-immunotherapy NSCLC space. The FDA has granted fast track designation to cesalatamig (AI-081), a bispecific antibody developed by OncoC4, for patients with non-small cell lung cancer (NSCLC) whose disease has progressed after concurrent or sequential PD-(L)1 immunotherapy and platinum-based chemotherapy — a population with very limited treatment options.
What makes it different? Cesalatamig simultaneously targets both PD-1 and VEGF, and reportedly binds VEGF with more than 40-fold higher affinity than bevacizumab-based bispecific competitors. It also incorporates Fc-silencing modifications to prevent depletion of PD-1–positive effector T cells — a key design feature aimed at preserving anti-tumor immune activity. The designation was supported by early safety and efficacy signals from the global BiPAVE-001 phase 1/2 program, running in both the US and China.
Key Takeaways:
Why it matters: For NSCLC patients who've already failed immunotherapy and chemotherapy, treatment options are scarce. Cesalatamig's dual-targeting approach and accelerated FDA pathway could bring a meaningful new option to this hard-to-treat population sooner.
